Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Ezrin shRNA
- Development stage
- Preclinical
- Lead developer
- National Cancer Institute
- Modality
- Viral-delivered RNAi → In Vivo RNAi → Gene Silencing → Gene Therapies, RNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Intratumoral
01
Overview
Ezrin shRNA is a short hairpin RNA (shRNA) designed to silence the expression of the Ezrin protein (also known as villin-2 or cytovillin). Ezrin is a member of the ERM (Ezrin-Radixin-Moesin) protein family and serves as a cross-linker between the plasma membrane and the actin cytoskeleton, playing a critical role in cell adhesion, migration, and organization of cell surface structures. In the context of oncology, Ezrin is often upregulated and associated with increased metastatic potential. Research, notably from the National Cancer Institute (NCI), has demonstrated that using shRNA to knockdown Ezrin can inhibit metastasis induced by HGF/Met signaling pathways in preclinical melanoma models. This modality works by triggering the RNA interference (RNAi) pathway, leading to the degradation of Ezrin mRNA and a subsequent reduction in protein levels, thereby impairing the invasive capabilities of tumor cells.
- Other names
- shRNA targeting EzrinEzrin-shRNAshRNA-Ezrin
02
Targets
EZR (Ezrin / EZR)
Beyond the preview
Go deeper on Ezrin shRNA.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Ezrin shRNA.